U.S. Capital Markets Stock News

Pure Cycle (PCYO) has posted its Q3 2026 numbers with total revenue of about US$8.2 million and basic EPS of US$0.12, set against trailing twelve month revenue of roughly US$33.7 million and EPS of US$0.61, underpinned by 8.2% earnings growth over the past year. Over recent quarters, the company has seen revenue move from around US$5.2 million with EPS of US$0.03 in Q2 2025 to US$11.2 million with EPS of US$0.25 in Q4 2025, then to US$8.2 million and EPS of US$0.12 in Q3 2026. This has left...

Butler National (BUKS) has put up a clean set of FY 2026 numbers, with fourth quarter revenue at US$27.7 million and basic EPS of US$0.09, alongside trailing twelve month revenue of US$98.0 million and EPS of US$0.34 that sit against reported earnings growth of 74.8% over the past year. Over recent periods the company has seen revenue progress from US$83.97 million on a trailing basis in FY 2025 to US$98.0 million in FY 2026. EPS over the same trailing window moved from US$0.19 to US$0.34,...

Wayfair's share price has rebounded in the last year, but with the stock still down 68.5% over five years and screening as overvalued on market multiples, the current level raises questions about how much of the recovery story is already reflected in the price. Over the past five years, Wayfair has delivered a total return that is down 68.5%, which highlights how deep the earlier drawdown was despite the more recent strength. Recent optimism around improving earnings expectations can support...

PriceSmart (PSMT) has released its Q3 2026 results, reporting revenue of about US$1.5b, basic EPS of roughly US$1.31 and net income, excluding extra items, of US$39.7m. The company’s quarterly revenue has moved from US$1.33b in Q4 2025 to US$1.38b in Q1 2026, US$1.50b in Q2 2026 and US$1.48b in Q3 2026. Over the same period, basic EPS ranged from US$1.02 to US$1.62, giving investors a clear view of top line scale and earnings power to track. With trailing 12 month EPS of about US$5.22 and a...

Clinical momentum and index changes frame Dianthus Therapeutics stock story Dianthus Therapeutics (DNTH) has kicked off its global Phase 3 EMERGE trial for claseprubart in generalized Myasthenia Gravis, while the stock was recently removed from several Russell value and growth benchmarks. The EMERGE trial will enroll about 195 acetylcholine receptor antibody positive generalized Myasthenia Gravis participants and compare subcutaneous claseprubart against placebo, with the Myasthenia Gravis...

Arbutus Biopharma stock has delivered a strong 126.4% return over the past three years, yet its current valuation checks and market multiples suggest the shares are not a clear bargain at recent levels. Over the last three years, Arbutus Biopharma has returned 126.4%, which puts extra focus on whether the current share price already reflects much of the good news investors are hoping for. Expectations around the company’s ability to turn its pipeline and research into durable cash flows can...

AZZ (AZZ) has opened fiscal 2027 with Q1 revenue of $448.5 million and basic EPS of $1.74, setting the tone for how its earnings story is evolving after a mixed year of growth and margin shifts. The company has seen quarterly revenue move from $421.9 million and EPS of $5.71 in Q1 2026 to $448.5 million and $1.74 in Q1 2027, against a backdrop where trailing 12 month EPS was $6.62 and net income was $198.4 million. This frames a results season in which investors are watching how profit...

Helen of Troy (HELE) opened fiscal Q1 2027 with revenue of US$402.1 million and basic EPS of US$1.54, while the trailing twelve months show revenue of US$1.8 billion and a basic EPS loss of US$17.87, highlighting the gap between the latest quarter and the broader period. Over the past few reported quarters, revenue has ranged from US$371.7 million to US$512.8 million and EPS has swung from a loss of US$19.65 to a profit of US$2.22. This sets the backdrop for how investors read this latest...

GATX (GATX) is in focus ahead of its 2026 second quarter earnings report, scheduled before the market opens on July 30, with a conference call and webcast for investors later that morning. See our latest analysis for GATX. At a share price of $174.95, GATX has seen modest short term share price momentum, with its 1 day and year to date share price returns in positive territory. Longer term total shareholder returns over 1, 3 and 5 years indicate that most gains have accrued over time rather...

Index reshuffle puts Kaiser Aluminum in focus Kaiser Aluminum (KALU) reported record first quarter 2026 net sales, conversion revenues, net income and adjusted EBITDA, alongside guidance for further improvement this year, just as the stock shifted across several Russell index classifications. For investors, this combination of strong recent performance and index changes raises practical questions about how Kaiser Aluminum might fit within portfolios that track value, growth or defensive...

With the Federal Reserve turning hawkish again and inflation sitting at 4.2%, investors are rethinking where they want their money. Rising rates, volatile growth stocks, and a rotation toward more resilient earnings stories are reshaping the opportunity set. This article looks at how that backdrop and the recent Fed pivot could affect U.S. Financial Services Stocks, and why some large, financially healthy companies may be better positioned than others. Below, you will find 3 stocks from our...

Innovex International (INVX) has just been added to multiple Russell growth indexes. This event can reshape who holds the stock as index funds and benchmarked investors adjust their portfolios. See our latest analysis for Innovex International. Over the past year Innovex International has combined a 10.01% year to date share price gain with a 54.03% total shareholder return. However, the 30 day share price return is down 11.85%, and the recent index additions appear to be resetting near term...

With major indexes riding an AI-fueled surge and the Buffett indicator sitting at a very high level relative to GDP, many investors are wondering where genuine value still exists and where risks might be building. This article looks at how that backdrop could affect a group of stocks flagged by a Value Stocks screener, focusing on low P/E and P/B ratios and a possible discount to intrinsic value. Below, you will find 3 stocks that the recent market setup may treat as relative beneficiaries...

In recent months, AllianceBernstein Holding has advanced efforts to lift profitability through office relocations and other margin accretion measures, while broadening its private markets platform via partnerships and new products in private credit, real estate, and alternative strategies. This push into higher-fee private markets and operational efficiency has sharpened investor focus on how the firm may reshape its earnings mix and risk profile. Next, we’ll examine how AllianceBernstein’s...

Microchip Technology has made its MPLAB XC Pro Compilers and Machine Learning Development Suite available for free to all users worldwide. The move also covers its functional safety compilers, broadening access to tools for safety-critical and AI-enabled embedded applications. This shift is expected to widen adoption of Microchip’s microcontroller platforms and deepen engagement with its development ecosystem. For investors watching NasdaqGS:MCHP, this software decision adds an important...

After a strong first month as a public company, Quantinuum’s near 30% gain over the past 30 days sits alongside a sharp split in valuation signals, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples screen the stock as expensive. The question for investors is how to weigh that tension against early stage quantum computing expectations and the stock’s low overall value score. Quantinuum has risen 29.5% over the past month,...

Earlier this year, Viking Therapeutics began a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor agonist being tested as a potential obesity treatment in adults with excess weight. This first-in-human study expands Viking’s obesity pipeline beyond its GLP‑1/GIP program, highlighting a multi-mechanism approach that could broaden its future treatment profile if development progresses successfully. We’ll now examine how adding VK3019 as an early-stage obesity...

In late June 2026, Avnet, Inc. (NasdaqGS: AVT) was removed from both the Russell 1000 Defensive and Russell 1000 Value-Defensive indices, reflecting a reclassification of the stock within those benchmarks. At the same time, research commentary highlighting Avnet’s attractive valuation metrics and positive earnings outlook has drawn fresh attention to the company as a potential value opportunity. Next, we’ll examine how Avnet’s index removal, alongside its perceived undervaluation and...

Kodiak Gas Services (KGS) is in focus after agreeing to a multi year power generation deal with Baker Hughes that targets up to 1.8 gigawatts of behind the meter capacity for growing AI and data center demand. See our latest analysis for Kodiak Gas Services. The Baker Hughes agreement follows Kodiak Gas Services joining the Russell 2000 Growth Defensive and Defensive Indexes in late June. It also comes alongside strong momentum, with an 85.6% year-to-date share price return and a 3-year total...

Prologis (NYSE:PLD) has taken its proposed all stock combination with SEGRO public, releasing a new presentation to SEGRO shareholders. The company is urging SEGRO investors to press their board to enter takeover talks, while SEGRO's board continues to resist the deal. This move shifts the discussion from private boardroom talks to a wider shareholder audience, highlighting Prologis' commitment to a public engagement campaign. Prologis enters this phase of the saga with its stock at $141.0...

Lindsay stock is coming off a challenging stretch, with the share price down about 26% over 5 years, yet the current intrinsic value estimate from a Discounted Cash Flow (DCF) model points to meaningful upside compared with where the market is pricing it today. At the same time, earnings based multiples look roughly in line with peers, which sets up a tension between a seemingly cheap cash flow profile and a share price that does not screen as obviously mispriced on simpler metrics. Over 5...

Index removal puts Precigen stock in focus Precigen (PGEN) has been removed from several Russell value and small cap benchmarks, an index reshuffle that can prompt passive funds to rebalance and temporarily change trading volumes or pricing. See our latest analysis for Precigen. For context, Precigen's share price has a 30 day share price return of 55.74% and a year to date share price return of 29.91%, while the 1 year total shareholder return of 192.63% and 3 year total shareholder return...

Pagaya Technologies and Upgrade have expanded their partnership to bring Pagaya’s AI-driven credit decisioning to Buy Now, Pay Later offerings. The collaboration targets BNPL solutions for travel merchants, broadening Pagaya’s reach beyond personal loans. The development highlights a move into new asset classes for Pagaya’s platform, with potential implications for its client mix and revenue sources. Pagaya Technologies (NasdaqCM:PGY) is drawing fresh attention as it extends its AI credit...

Southwest Airlines and Korean carrier Air Premia have entered into their first-ever interline partnership. The agreement connects Air Premia routes from South Korea with more than 120 destinations across the Southwest Airlines network. The partnership opens new East Asia connectivity for Southwest customers and expands options for travelers originating in South Korea. For investors watching Southwest Airlines, ticker NYSE:LUV, this partnership introduces an additional international angle to...